An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Launched by TARGET PHARMASOLUTIONS, INC. · Oct 1, 2018

Keywords

ClinConnect Summary

The TARGET-HBV study is looking at how patients with chronic hepatitis B (CHB) are treated and what outcomes they experience in real-life settings. This second phase of the study will gather information from patients across the US and Canada who are receiving standard care for CHB. By collecting data from both large hospitals and community clinics, the study aims to better understand how antiviral treatments work and how they affect patients' health over time.

To participate in this study, you need to be at least 18 years old and currently being treated for chronic hepatitis B, whether you have successfully managed the virus or have other related conditions. If you choose to join, you can expect to share your health information with researchers who will use it to improve the understanding and management of hepatitis B. It's important to note that individuals with a history of HIV or liver transplants cannot participate. This study is a valuable opportunity to contribute to important research that could benefit many others with similar health concerns.

Gender

ALL

Eligibility criteria

• • Inclusion
• • 1. Male or female patients, age ≥18 years
• • 2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis
• • Exclusion
• • 1. Inability to provide written informed consent
• • 2. Known history of Human Immunodeficiency Virus (HIV)
• • 3. History of liver transplantation